{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:07:04Z","timestamp":1776866824939,"version":"3.51.2"},"update-to":[{"DOI":"10.1002\/14651858.cd013731","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000}}],"reference-count":119,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013731.pub2","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:43:17Z","timestamp":1717591397000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene therapy for people with hepatocellular carcinoma"],"prefix":"10.1002","volume":"2024","author":[{"given":"Cho","family":"Naing","sequence":"additional","affiliation":[{"name":"Division of Tropical Health and Medicine; James Cook University; Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Medicine; Newcastle University Medicine Malaysia; Johor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Htar Htar","family":"Aung","sequence":"additional","affiliation":[{"name":"School of Medicine; IMU University; Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah Htet","family":"Htet","sequence":"additional","affiliation":[{"name":"School of Medicine; IMU University; Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrinka","family":"Nikolova","sequence":"additional","affiliation":[{"name":"Cochrane Hepato-Biliary Group; Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"10.1002\/14651858.CD013731.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/COC.0b013e3181fe4688","article-title":"Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma","volume":"37","author":"Chen","year":"2014","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.cgt.7700431","article-title":"Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma","volume":"9","author":"Habib","year":"2002","journal-title":"Cancer Gene Therapy"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-07-0499","article-title":"Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma","volume":"13","author":"Li","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10.1002\/14651858.CD013731.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy pexastimogene devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0005|cit5","unstructured":"A phase 2b study of modified vaccinia virus to treat patients advanced liver cancer who failed sorafenib (TRAVERSE) clinicaltrials.gov\/ct2\/show\/NCT01387555"},{"issue":"5","key":"10.1002\/14651858.CD013731.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/CAD.0b013e32832a2df9","article-title":"Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial","volume":"20","author":"Tian","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0007|cit7","unstructured":"Preliminary results for the double-dose adenovirus-mediated adjuvant therapy improving outcome of liver transplantation in patients with advanced hepatocellular carcinoma clinicaltrials.gov\/ct2\/show\/NCT02202564"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/hum.2017.114","article-title":"Double-dose adenovirus-mediated adjuvant gene therapy improves liver transplantation outcomes in patients with advanced hepatocellular carcinoma","volume":"29","author":"Zhu","year":"2018","journal-title":"Human Gene Therapy"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-1-4939-2727-2_19","volume-title":"Gene Therapy of Solid Cancers: Methods and Protocols, Methods in Molecular Biology","volume":"1317","author":"Breitbach","year":"2015"},{"issue":"8","key":"10.1002\/14651858.CD013731.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12032-014-0095-4","article-title":"Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5","volume":"31","author":"Dong","year":"2014","journal-title":"Medical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD013731.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.3748\/wjg.v17.i16.2143","article-title":"p53 Gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up","volume":"17","author":"Guan","year":"2011","journal-title":"World Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD013731.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nature Medicine"},{"issue":"38","key":"10.1002\/14651858.CD013731.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.3748\/wjg.v12.i38.6085","article-title":"Gene therapy of liver cancer","volume":"12","author":"Hernandez-Alcoceba","year":"2006","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1099\/vir.0.000098","article-title":"Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma","volume":"986","author":"Jebar","year":"2015","journal-title":"Journal of General Virology"},{"issue":"51","key":"10.1002\/14651858.CD013731.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S0959-8049(16)31135-2","article-title":"Intratumoral injection of the oncolytic immunotherapeutic Pexa-Vec (JX-594) in liver tumors and hepatocellular carcinoma: recommendations for clinical practice","volume":"3","author":"Lencioni","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12013-014-0167-2","article-title":"Trans-arterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience","volume":"71","author":"Liu","year":"2015","journal-title":"Cell Biochemistry and Biophysics"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0017|cit17","unstructured":"Radiotherapy in hepatocellular carcinomas after hepatectomy with narrow margin (<1 cm) or portal vein thrombosis (RHCC) clinicaltrials.gov\/ct2\/show\/NCT02309788"},{"issue":"6","key":"10.1002\/14651858.CD013731.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013731.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1053\/j.gastro.2005.03.024","article-title":"Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients","volume":"128","author":"Penuelas","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD013731.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/etm.2020.9145","article-title":"Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer","volume":"20","author":"Qu","year":"2020","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013731.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/cgt.2010.40","article-title":"A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma","volume":"17","author":"Sangro","year":"2010","journal-title":"Cancer Gene Therapy"},{"issue":"4","key":"10.1002\/14651858.CD013731.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/hep.14.16","article-title":"Immunotherapy of hepatocellular carcinoma","volume":"1","author":"Sangro","year":"2014","journal-title":"Hepatic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013731.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nature Reviews Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/gut.50.1.130","article-title":"Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies","volume":"50","author":"Schmitz","year":"2002","journal-title":"Gut"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0025|cit25","unstructured":"Gene therapy in treating patients with cancer of the liver clinicaltrials.gov\/ct2\/show\/NCT00003147"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0026|cit26","unstructured":"Liver transplantation with ADV-TK gene therapy improves survival in patients with advanced hepatocellular carcinoma www.clinicaltrials.gov\/ct2\/show\/NCT00300521"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0027|cit27","unstructured":"Follow-up study of subjects previously enrolled in poxviral vector gene transfer studies clinicaltrials.gov\/ct2\/show\/NCT00451022"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0028|cit28","unstructured":"rRp450 \u2013 phase I trial in liver metastases and primary liver tumors clinicaltrials.gov\/ct2\/show\/NCT01071941"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0029|cit29","unstructured":"Phase III trial of transcatheter arterial chemoembolization (TACE) plus recombinant human adenovirus type 5 Injection for unresectable hepatocellular carcinoma (HCC) clinicaltrials.gov\/ct2\/show\/NCT01869088"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0030|cit30","unstructured":"Anti-GPC3 CAR T for treating patients with advanced HCC clinicaltrials.gov\/ct2\/show\/NCT02395250"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0031|cit31","unstructured":"Trans-catheter chemo-embolization combined with rAd-p53 gene injection in treatment of advanced hepatocellular carcinoma clinicaltrials.gov\/ct2\/show\/NCT02418988"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0032|cit32","unstructured":"Trans-catheter arterial embolization combined with p53 gene therapy for treatment of advanced hepatocellular carcinoma clinicaltrials.gov\/ct2\/show\/NCT02509169"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0033|cit33","unstructured":"p53 gene therapy in treatment of diabetes concurrent with hepatocellular carcinoma clinicaltrials.gov\/ct2\/show\/NCT02561546"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0034|cit34","unstructured":"Glypican 3-specific chimeric antigen receptor expressing T cells for hepatocellular carcinoma (GLYCAR) (GLYCAR) clinicaltrials.gov\/ct2\/show\/NCT02905188"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0035|cit35","unstructured":"Multicenter RCT of ADV-TK gene therapy improving the outcome of liver transplantation for advanced HCC clinicaltrials.gov\/ct2\/show\/NCT03313596"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0036|cit36","unstructured":"Study of ACTR T cell product in combination with trastuzumab in subjects with HER2-positive advanced solid tumor cancers clinicaltrials.gov\/ct2\/show\/NCT03680560"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0037|cit37","unstructured":"Interleukin-15 and -21 armored glypican-3-specific chimeric antigen receptor expressed in T cells for pediatric solid tumors clinicaltrials.gov\/ct2\/show\/NCT04715191"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013731.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD013731.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0043|cit43","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/hum.2019.197","article-title":"Public acceptability of gene therapy and gene editing for human use: a systematic review","volume":"31","author":"Delhove","year":"2020","journal-title":"Human Gene Therapy"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1186\/s12885-021-08904-3","article-title":"Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database","volume":"21","author":"Ding","year":"2021","journal-title":"BMC Cancer"},{"issue":"6372","key":"10.1002\/14651858.CD013731.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1002\/14651858.CD013731.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0048|cit48","unstructured":"European Society for Medical Oncology (ESMO) Guidelines Committee 2021 Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines www.esmo.org\/guidelines\/guidelines-by-topic\/gastrointestinal-cancers\/hepatocellular-carcinoma\/eupdate-hepatocellular-carcinoma-treatment-recommendations"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0049|cit49","first-page":"121","article-title":"Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001\/83\/EC","volume":"324","author":"European Parliament and Council","year":"2007","journal-title":"Official Journal of the European Union"},{"issue":"12","key":"10.1002\/14651858.CD013731.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hep.24680","article-title":"Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis","volume":"55","author":"Fuks","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD013731.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"Journal of Gene Medicine"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0054|cit54","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1389450114666140106095151","article-title":"Targeting tumor suppressor networks for cancer therapeutics","volume":"15","author":"Guo","year":"2014","journal-title":"Current Drug Targets"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"19","key":"10.1002\/14651858.CD013731.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00535-008-2262-x","article-title":"Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"44","author":"Hashimoto","year":"2009","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.cgt.7700542","article-title":"Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes","volume":"9","author":"Hermiston","year":"2002","journal-title":"Cancer Gene Therapy"},{"issue":"38","key":"10.1002\/14651858.CD013731.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.3748\/wjg.v12.i38.6085","article-title":"Gene therapy of liver cancer","volume":"12","author":"Hernandez-Alcoceba","year":"2006","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0060|cit60","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page M Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0061|cit61","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0062|cit62","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0063|cit63","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023) Available from training.cochrane.org\/handbook\/current"},{"issue":"7211","key":"10.1002\/14651858.CD013731.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD013731.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4193\/Rhino11.239","article-title":"Gene therapy and nasopharyngeal carcinoma","volume":"50","author":"Hughes","year":"2012","journal-title":"Rhinology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0066|cit66","unstructured":"International Council for Harmonisation of technical requirements for pharmaceuticals for human use (ICH) ICH Harmonised Guideline. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2) database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2288-14-34","article-title":"The thresholds for statistical and clinical significance \u2013 a five-step procedure for evaluation of intervention effects in randomised clinical trials","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2288-10-90","article-title":"Evidence at a glance: error matrix approach for overviewing available evidence","volume":"10","author":"Keus","year":"2010","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.jceh.2014.03.049","article-title":"Role of supportive care for terminal stage hepatocellular carcinoma","volume":"Suppl 3","author":"Kumar","year":"2014","journal-title":"Journal of Clinical and Experimental Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013731.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes and Diseases"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0071|cit71","unstructured":"Lefebvre C Manheimer E Glanville J on behalf of the Cochrane Information Retrieval Methods Group Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0072|cit72","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"7","key":"10.1002\/14651858.CD013731.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1053\/j.gastro.2005.03.001","article-title":"Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma","volume":"128","author":"Li","year":"2005","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD013731.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/ijc.21585","article-title":"Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma","volume":"118","author":"Li","year":"2005","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/d41586-022-00025-6","article-title":"Stamp out fake clinical data by working together","volume":"601","author":"Lisa","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013345.pub2","article-title":"The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma","author":"Liu","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"2","key":"10.1002\/14651858.CD013731.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013731.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/mt.2016.10.","article-title":"Genome editing technologies for gene and cell therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1002\/14651858.CD013731.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0081|cit81","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0082|cit82","unstructured":"Micklus A Gene therapy: a paradigm shift in medicine pharmaintelligence.informa.com\/~\/media\/informa-shop-window\/pharma\/whitepapers\/dmhc-gene-therapy-whitepaper.pdf"},{"issue":"17","key":"10.1002\/14651858.CD013731.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.79.17.11434-11442.2005","article-title":"Large-scale analysis of adeno-associated virus vector integration sites in normal human cells","volume":"79","author":"Miller","year":"2005","journal-title":"Journal of Virology"},{"issue":"6","key":"10.1002\/14651858.CD013731.pub2-BIB0084|cit84","first-page":"1015","article-title":"Sorafenib-induced erythema multiforme: three cases","volume":"21","author":"Namba","year":"2012","journal-title":"European Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013731.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"issue":"21","key":"10.1002\/14651858.CD013731.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013731.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0088|cit88","unstructured":"National Institute for Health and Care Excellence NICE final draft guidance approves life-changing gene therapy for treating spinal muscular atrophy www.nice.org.uk\/news\/article\/nice-approves-life-changing-gene-therapy-for-treating-spinal-muscular-atrophy"},{"issue":"3","key":"10.1002\/14651858.CD013731.pub2-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004787.pub2","article-title":"Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma","author":"Oliveri","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013731.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007652.pub7","article-title":"Gene therapy for sickle cell disease","author":"Olowoyeye","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD013731.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/CRT.1000200","article-title":"Rescue of sorafenib-pretreated advanced hepatocellular carcinoma with tamoxifen","volume":"3","author":"Ottaviano","year":"2017","journal-title":"Clinical Research and Trial"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0092|cit92","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0093|cit93","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD013731.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"International Journal of Cancer"},{"issue":"24","key":"10.1002\/14651858.CD013731.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/ijc.30211","article-title":"International trends in liver cancer incidence, overall and by histologic subtype, 1978\u20132007","volume":"139","author":"Petrick","year":"2016","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","article-title":"Future of hepatocellular carcinoma incidence in the United States forecast through 2030","volume":"34","author":"Petrick","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013731.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","article-title":"Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project","volume":"118","author":"Petrick","year":"2018","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013731.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0168-8278(00)80082-3","article-title":"The potential of gene therapy in the treatment of hepatocellular carcinoma","volume":"32","author":"Qian","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD013731.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/cancers11091265","article-title":"Current status of gene therapy in hepatocellular carcinoma","volume":"11","author":"Reghupaty","year":"2019","journal-title":"Cancers"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0102|cit102","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm0397-313","article-title":"Adenovirally transferred p16INK4\/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death","volume":"3","author":"Sandig","year":"1997","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013731.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study","volume":"187","author":"Savovic","year":"2018","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0105|cit105","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1479-5876-12-93","article-title":"Role of estrogen in hepatocellular carcinoma: is inflammation the key?","volume":"12","author":"Shi","year":"2014","journal-title":"Journal of Translational Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013731.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"E105","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Erratum in PMID: 37199193","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD013731.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2014.123","article-title":"A hybrid adenoviral vector system achieves efficient long-term gene expression in the liver via piggyBac transposition","volume":"26","author":"Smith","year":"2015","journal-title":"Human Gene Therapy"},{"issue":"5","key":"10.1002\/14651858.CD013731.pub2-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012069.pub2","article-title":"Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents \u2013 assessment of adverse events in non-randomised studies","author":"Storeb\u00f8","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0110|cit110","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017 Available from ctu.dk\/tsa\/learn-more"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0112|cit112","unstructured":"TSA \u2013 Trial Sequential Analysis Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2013 Rigshospitalet 2021"},{"issue":"10","key":"10.1002\/14651858.CD013731.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"e5943","DOI":"10.5812\/hepatmon.5943","article-title":"Risk of hepatocellular carcinoma in workers exposed to chemicals","volume":"12","author":"Uccello","year":"2012","journal-title":"Hepatitis Monthly"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0114|cit114","unstructured":"US National Health Library How does gene therapy work? medlineplus.gov\/genetics\/understanding\/therapy\/procedures\/"},{"issue":"7","key":"10.1002\/14651858.CD013731.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013731.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in a random-effects meta-analysis","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013731.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"6","DOI":"10.18632\/oncotarget.6781","article-title":"Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1002\/14651858.CD013731.pub2-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013731","article-title":"Gene therapy for people with hepatocellular carcinoma","author":"Naing","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T03:21:05Z","timestamp":1760584865000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013731.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":119,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013731.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}